PMID- 29603773
OWN - NLM
STAT- MEDLINE
DCOM- 20190515
LR  - 20190515
IS  - 1096-8652 (Electronic)
IS  - 0361-8609 (Linking)
VI  - 93
IP  - 6
DP  - 2018 Jun
TI  - Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple 
      myeloma patients carrying the 17p deletion: An observational multi-center 
      retrospective study.
PG  - 810-815
LID - 10.1002/ajh.25098 [doi]
AB  - Del17p is a genomic imbalance occurring in  approximately 7%-10% of myeloma at diagnosis newly 
      diagnosed myeloma patients (NDMM) and comprises a poor prognostic factor. The 
      goal of this study is to analyze real world data and outcomes among NDMM patients 
      carrying 17p deletion. We report an observational, retrospective, multicenter 
      study. Sixty consecutive patients diagnosed with multiple myeloma in the 8 
      participating centers diagnosed between 1/2008 and 1/2016 proven to carry 17p 
      deletion by means of fluorescence in situ hybridization (FISH) were identified. 
      Most received a bortezomib-based induction, over half underwent autologous 
      hematopoietic cell transplantation (HCT); 30% of the patients gained early access 
      to new novel agents via clinical trials, access programs or private insurance. 
      Overall response rate (ORR) after induction was 85%; 94% for transplant eligible 
      (TE); and 75% for transplant ineligible (NTE), and declined in subsequent 
      treatment lines, 64% achieved >/= VGPR. Median overall survival (OS) was 43 months; 
      median progression free survival (PFS) was 11 months, 19 months for TE and 7 for 
      NTE. In multivariate analysis: higher M-Spike, presence of extramedullary 
      disease, and >50% of cells baring del17p were associated with adverse PFS; 
      Autologous HCT and higher hemoglobin were associated with longer PFS; OS was 59 
      months for patients with early access to newer agents. Older age and higher 
      M-Spike levels were associated with adverse OS, Autologous HCT was associated 
      with favorable OS, 59.7 vs 28.7 months for NTE patients. Despite the improvement 
      achieved with autologous HCT and new novel agents, the prognosis of patients with 
      17p deletion is still inferior, emphasizing the need for novel approaches.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Cohen, Yael C
AU  - Cohen YC
AUID- ORCID: 0000-0002-9061-7287
AD  - Tel-Aviv Sourasky medical Center, Israel.
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Israel.
FAU - Saranga, Avi
AU  - Saranga A
AD  - Tel-Aviv Sourasky medical Center, Israel.
FAU - Gatt, Moshe E
AU  - Gatt ME
AUID- ORCID: 0000-0002-9426-4482
AD  - Hadassah Hebrew University Medical Center, Israel.
FAU - Lavi, Noa
AU  - Lavi N
AD  - Rambam Health Care Campus, Haifa, Israel.
FAU - Ganzel, Chezi
AU  - Ganzel C
AUID- ORCID: 0000-0002-1722-4807
AD  - Shaare Zedek Medical Centre, Jerusalem, Israel.
FAU - Magen, Hila
AU  - Magen H
AD  - Institute of Haematology, Rabin Medical Center, Petah Tikva, Israel; Sackler 
      Faculty of Medicine, Tel-Aviv University, Ramat Aviv, Israel.
FAU - Avivi, Irit
AU  - Avivi I
AD  - Tel-Aviv Sourasky medical Center, Israel.
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Israel.
FAU - Tadmor, Tamar
AU  - Tadmor T
AD  - Bnai-Zion Medical Center, Israel.
AD  - The Ruth and Bruce Rappaport Faculty of Medicine, Technion Haifa, Israel.
FAU - Suriu, Celia
AU  - Suriu C
AD  - Galilee Medical Centre, Nahariya and Azrieli Faculty of Medicine, Bar Ilan 
      University, Safed, Israel.
FAU - Jarchowsky Dolberg, Osnat
AU  - Jarchowsky Dolberg O
AD  - Meir Medical Center, Kfar-Saba, Israel.
FAU - Papushado, Amitai
AU  - Papushado A
AD  - Tel-Aviv Sourasky medical Center, Israel.
FAU - Trestman, Svetlana
AU  - Trestman S
AD  - Tel-Aviv Sourasky medical Center, Israel.
FAU - Ram, Ron
AU  - Ram R
AD  - Tel-Aviv Sourasky medical Center, Israel.
AD  - Sackler Faculty of Medicine, Tel-Aviv University, Israel.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20180428
PL  - United States
TA  - Am J Hematol
JT  - American journal of hematology
JID - 7610369
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chromosomes, Human, Pair 17/*genetics
MH  - Female
MH  - *Gene Deletion
MH  - Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/*genetics/mortality/*therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Analysis
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2018/04/01 06:00
MHDA- 2019/05/16 06:00
CRDT- 2018/04/01 06:00
PHST- 2018/01/20 00:00 [received]
PHST- 2018/03/21 00:00 [revised]
PHST- 2018/03/22 00:00 [accepted]
PHST- 2018/04/01 06:00 [pubmed]
PHST- 2019/05/16 06:00 [medline]
PHST- 2018/04/01 06:00 [entrez]
AID - 10.1002/ajh.25098 [doi]
PST - ppublish
SO  - Am J Hematol. 2018 Jun;93(6):810-815. doi: 10.1002/ajh.25098. Epub 2018 Apr 28.